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Objective: We sought to explore the yield of transrectal ultrasound (TRUS) in chronic prostatitis/chronic
pelvic pain syndrome (CP/CPPS).
Materials and methods: The records of all patients, who were referred for TRUS caused by CP/CPPS, were
retrospectively reviewed. Digital rectal examination (DRE) was performed before TRUS. The following
parameters were recorded: prostatic length; width; height; volume; external border; peripheral zone
(PZ); transitional zone (TZ); TZ/PZ border; seminal vesicles appearance (SV); presence of median lobe;
dilation of vas deferens (VD) or ejaculatory duct (ED); and presence of signiﬁcant postvoid residual (PVR).
Unique sonographic ﬁndings, if present, were recorded as well. Data were compared to those of an age-
matched control group that had undergone the same imaging for other reasons.
Results: Two hundred and sixteen patients with suspected CP/CPPS underwent DRE and TRUS. Per DRE,
their prostates appeared smaller and homogeneous compared with the control group. Differences seen in
TRUS between the study and the control groups, respectively, were as follows: fewer irregularities, fewer
hypoechoic areas in PZ; fewer cystic spaces, fewer enlarged median lobes in TZ; less ED dilation; more
calciﬁcations; more VD dilation; and more periurethral vascularity. No differences were seen in SV pa-
rameters and in PVR. None of the patients has been given different diagnosis or treatment following
TRUS.
Conclusion: The ﬁndings of TRUS studies in patients with suspected CP/CPPS are not pathognomonic for
this entity, and TRUS is therefore considered as having very little yield in this setting.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic prostatitis (CP) or chronic pelvic pain syndrome (CPPS)
encompasses a wide variety of clinical complaints, including peri-
neal or suprapubic pain, painful ejaculation or urination, and
referred pain to the groin and testicles.1
Previous bacterial infection may serve as a possible etiology, yet
it is not uncommon to repeatedly obtain sterile semen, blood, or
urine cultures with leukocytes as the only sign of an ongoing
chronic inﬂammatory process.2
Whatever the reason, the patients eventually present to the
physicians with various complaints that may not respond, orhaim Sheba Medical Center,
an).
ociation. Published by Elsevier Tapartially respond, to treatment with a single regimen or combined
therapeutic regimens including alpha blockers, nonsteroidal anti-
inﬂammatory drugs, serotonin-speciﬁc reuptake inhibitors, or
opiates,3 a fact that makes treatment in this particular group of
patients remarkably frustrating to both patients and physicians.
Historic studies pointed out sonographic ﬁndings that may be
suggestive of CP.1,4e6 Consequently, many physicians have been
referring patients with CP/CPPS to undergo transrectal ultrasound
(TRUS) imaging in an attempt to obtain a deﬁnitive diagnosis. Over
time, this approach has become a common practice, categorized by
some as optional7 and eventually has been included in the most
recent European Association of Urology (EAU) guidelines on CPPS.3
Yet, no pathognomonic sonographic ﬁndings that warrant careful
attention have ever been deﬁned. Despite being a common practice
that has been formally approved, review of the literature reveals
only one study that compared sonographic ﬁndings of nonbacterialiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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ﬁndings based upon a small sample of patients.
In the current study, sonographic ﬁndings of patients with CP/
CPPS were compared to those of age-matched controls in an
attempt to conclude whether TRUS can serve as a diagnostic or
therapeutic tool in cases suspicious for CP/CPPS.2. Materials and methods
Following an approval given by Assuta Medical Center Institu-
tional Review Board, we retrospectively reviewed the records of all
patients who were referred for TRUS imaging by various commu-
nity urologists between the years 2005 and 2013 due to clinical
complains, physical examination, and laboratory ﬁndings sugges-
tive of CP/CPPS.
Before the imaging, the examinee emptied his bladder. There-
after, while in the left lateral decubitus position, the patient un-
derwent a digital rectal examination (DRE) by a single TRUS
operator to further estimate prostate volume, borders, symmetry,
ﬁrmness, mobility, and the presence of suspicious mass.
TRUS was performed using a Prostate Biplane Transducer 8808e
(5-10 MHz, BK Medical, Herlev, Denmark).
The prostate was assessed in sagittal and transverse views and
the following parameters were recorded: length; width; height;
volume; appearance of external borders (preserved/not preserved);
peripheral zone (PZ; homogeneous/heterogeneous); transitional
zone (TZ; homogeneous/heterogeneous/presence of calciﬁcations
or cystic spaces); TZ/PZ border (preserved/not preserved); seminal
vesicle [SV; normal/dilated (i.e., >10-mm width, >45-mm length)/
cysts]; presence of median lobe; dilation of vas deferens (VD) or
ejaculatory ducts (ED) if present; periurethral vascularity, if present
(i.e., the appearance of hypoechoic area surrounded by increased
vascular supply); presence of signiﬁcant postvoid residual (PVR;
i.e.,  200 mL). Unique sonographic ﬁndings, if present, were
recorded as well.
The aforementioned data were compared with the same data
recorded in an age-matched control group that had undergone the
same imaging for reasons other than CP/CPPS. In accordance with
examinee's age, etiologies for TRUS in the control group were
infertility work-up; elevated prostate-speciﬁc antigen (PSA)
without any associated symptoms; presence of suspicious mass or
nodule; prostate weight estimation before surgery.
Exclusion criteria for the control group were presence of hem-
atospermia as a single symptom or sonographic absence of at least
one VD/SV.
Data are presented as median (interquartile range, IQR) or n (%)
unless otherwise speciﬁed. Statistical analyses were performed
using the R version 2.15 software (the R Foundation for Statistical
Computing, Vienna, Austria) with rms and Hmisc libraries. Com-
parisons between the groups were carried out using rank sign and
Fisher's exact tests for continuous and categorical variables,
respectively, as appropriate. All tests were two-sided. Any p values
< 0.05 were considered statistically signiﬁcant.3. Results
Two hundred and sixteen male patients aged 42 years (35e50
years) have undergone TRUS imaging for further assessment of
clinical symptoms suggestive of CP/CPPS. The number of cases in
accordance with age group is presented in Figure 1.
DRE ﬁndings and age distribution for both study and control
groups are detailed in Table 1.
On DRE, the prostates in the study group appeared smaller
(15.5 cc vs. 25 cc, p < 0.001) and less suspicious in terms ofirregularity or mass presence compared with the control group
(3.2% vs. 9.3%, p ¼ 0.016).
The clinical ﬁnding of smaller prostates in the CP/CPPS group
was further reinforced by TRUS imaging for all dimensions
(Table 2).
TRUS ﬁndings are presented in Table 3. Regarding the PZ, fewer
irregularities and hypoechoic areas were seen in the study group
compared with the control group (p < 0.001).
In the TZ, fewer cystic spaces and median lobes were detected
(p ¼ 0.008 and p ¼ 0.001, respectively); however, the study group
demonstrated statistically signiﬁcantly higher incidence of calciﬁ-
cations compared with the control group (51.4% vs. 38%, p ¼ 0.007).
No difference was seen between the two groups in all SV pa-
rameters (enlargement, cystic spaces, and calciﬁcations); however,
VD dilation, either unilateral or bilateral, was seen more frequently
in the study group compared with the control group (19.1% vs.
11.6%, p ¼ 0.044).
ED dilation/calciﬁcations were seen less frequently in the study
group compared with the control group (5.1% vs. 11.6%, p ¼ 0.02).
Periurethral vascularity was demonstrated in six of 216 patients
in the study group (2.8%) compared with zero patients in the
control group (p ¼ 0.03).
There were no differences in the incidence of signiﬁcant PVR
between the two groups (p ¼ 0.831).
Selected sonographic ﬁndings in TZ, SV, VD, and ED are
demonstrated in Figures 2e4.
No other unique sonographic ﬁndings were recorded, neither in
the study group nor in the control group.
None of the patients in the study group has been given a
different diagnosis or treatment following TRUS.
4. Discussion
Ever since the introduction of ultrasonography as a possible
diagnostic and therapeutic tool in prostatic diseases, there have
been several attempts to identify sonographic ﬁndings suggestive
of CP/CPPS in various zones of the prostate and its accompanying
structures.
Dobble and Carter8 found that in cases of acute infection, several
characteristic features may be identiﬁed, among which are high
density and midrange echoes, echo-lucent zones, and capsular ir-
regularity and thickening. Follow-up TRUS, however, showed res-
olution of the echo-lucent zones to normal, midrange, or high-
density echoes. Similarly, in our study, hypoechoic and irregular
areas were seen in only 2.3% and 2.3% of the cases in the study
group compared with 17.8% and 17.3% in the control group,
respectively.
In the current study, TZ calciﬁcations were seenmore frequently
in cases of CP/CPPS syndrome compared with the control group.
This observation has been reported in other studies as well.4,5,9,10
Ludwig et al,5 evaluating sonographic characteristics of 88 pa-
tients with CP and 53 patients with prostatodynia, demonstrated
statistically signiﬁcant accumulation of prostatic calciﬁcations in
cases of CP, and concluded that prostatic calciﬁcations, particularly
of diffuse type, often appear in true inﬂammation. In another
study,10 multiple intraprostatic calciﬁcations were strongly corre-
lated with laboratory ﬁndings suggestive of inﬂammation, such as
positive cultures and high white blood cells counts in expressed
prostatic secretions, albeit no clinical difference was noticed
comparing cases whereby stones were detected with stone-free
cases. In other words, the presence of intraprostatic calciﬁcations
probably lacks clinical signiﬁcance.
Geramoutsos et al9 also explored prostatic calciﬁcations in pa-
tients with CP/CPPS, and identiﬁed two types: Type A e small
multiple calciﬁcations and Type B e larger, coarser calculi.
Figure 1. Cases distribution in accordance with age group.
Table 1
Age distribution and digital examination.
Variable Study group Control group p
No. of patients 216 216
Age, y 42 (35e50) 45 (35e50) 0.393
Prostate volume, cc 15.5 (15e25) 25 (15e30) < 0.001
Prostate ﬁrmness 1 (0.5) 7 (3.2) 0.068
Prostate symmetry 212 (98.1) 213 (98.6) 1.000
Preserved prostatic borders 214 (99.1) 214 (99.1) 1.000
Prostate mobility 214 (99.1) 214 (99.1) 1.000
Palpated mass/irregularity 7 (3.2) 20 (9.3) 0.016
Data are presented as n (%) or n (range).
Table 3
Transrectal ultrasound ﬁndings.
Variable Study group Control group p
PZ
Heterogeneous 7 (3.2) 1 (0.5) 0.068
Irregularity 5 (2.3) 37 (17.3) <0.001
Hypoechoic areas 5 (2.3) 38 (17.8) <0.001
TZ
Heterogeneous 3 (1.4) 2 (1.0) 1.000
Calciﬁcations 111 (51.4) 82 (38.0) 0.007
Cystic spaces 12 (5.6) 29 (13.4) 0.008
Median lobe 16 (7.4) 39 (18.1) 0.001
TZ/PZ borders preserved 214 (99.1) 199 (94.3) 0.006
SV
Anatomical abnormalities 104 (48.1) 93 (43.1) 0.334
Enlargement, any 69 (32.1) 80 (37.2) 0.311
Unilateral 14 (6.5) 14 (6.5)
Bilateral 55 (25.6) 66 (30.7)
Cystic spaces, any 67 (31.2) 53 (24.5) 0.133
Unilateral 13 (6.0) 8 (3.7)
Bilateral 54 (25.1) 45 (20.8)
Calciﬁcations, any 4 (1.9) 2 (0.9) 0.685
Unilateral 2 (0.9) 2 (0.9)
Bilateral 2 (0.9) 0
VD
Dilation, any 41 (19.1) 25 (11.6) 0.044
D.E. Zilberman et al. / Urological Science 27 (2016) 40e4442In most cases, Type A calciﬁcations were incidental ﬁndings
strongly associated with advanced age, whereas Type B calciﬁca-
tions were strongly correlated with CP/CPPS. The authors' concept
was that larger stones may cause dilation of prostatic ducts, sub-
sequent loss of epithelial lining, and ultimate intraprostatic ﬁbrosis.
This theory may explain why in our study the prostates, which
demonstrated higher incidence of calciﬁcations compared with the
control group, were palpated and measured smaller in all di-
mensions compared with the control group.
Alteration in SV structure is believed to serve as a possible eti-
ology for CP/CPPS syndrome. Di Trapani et al6 explored sonographic
characteristics in 121 patients with CP; in 61.5% of these patients SV
abnormalities were detected, including elongation, dilation,
asymmetry, and septal thickening inside the SV.
The authors concluded that such ﬁndings may reﬂect true in-
ﬂammatory disease involving both prostate and SV.5,6
In another study, Dik et al1 detected medial prostatic cyst in 34
patients, of whom 26 patients (76%) had prostatic-like symptoms.
The cysts were marsupialized transurethrally in 18 patients.
Symptoms resolved in 14 patients (78%) and improved in 17 pa-
tients (94%) in 18 months' follow-up. TRUS was hence recom-
mended in order to rule out the presence of medial prostatic cyst or
SV dilation.
Other studies, however, did ﬁnd evidence for SV dilation in cases
of CP/CPPS, yet its prevalence was low and inconclusive.4,11 In our
study, SV abnormalities (i.e., enlargement, presence of cystic
spaces, calciﬁcations) and ED dilation were not found to be more
frequent in cases of CP/CPPS compared with controls, yet, the onlyTable 2
Prostatic dimensions as recorded by transrectal ultrasound.
Variable Study group Control group p
Prostate volume, cc 16.4 (12.2e21.7) 20.0 (13.8e34.4) < 0.001
Prostate length, mm 30 (26e34) 33 (28e38) < 0.001
Prostate height, mm 25 (22e29) 27 (22e36) <0.001
Prostate width, mm 43 (39e47) 45 (40e50) 0.003
Data are presented as n (range).ﬁnding that may hint involvement of extraprostatic structures in
the inﬂammatory process was VD dilation.
Periurethral involvement was noted in few studies. Grifﬁths
et al12 noted a periurethral “halo” in 40 patients with chronic
recurrent abacterial prostatitis. In another study this was deﬁned as
“periurethral irregularity” and was noted in 7.1% of the study
group,11 whereas another study6 mentions constant dilation of the
Santorini plexus. In our study, periurethral irregularity or vascu-
larity was seen in six of 216 patients and was found statistically
signiﬁcant, yet the number was too small to draw substantial
conclusions.
The main problem with the aforementioned previous studies is
that their ﬁndings have not been compared to a control group;
hence, it cannot be concluded whether these ﬁndings were sug-
gestive of true inﬂammatory process or incidental, sporadic, and
nonspeciﬁc features. The only attempt of comparison was made by
de la Rosette et al,4 who evaluated sonographic ﬁndings of 22Unilateral 15 (7.0) 8 (3.7)
Bilateral 26 (12.1) 17 (7.9)
ED
Dilation/calciﬁcations, any 11 (5.1) 25 (11.6) 0.022
Unilateral 10 (4.6) 24 (11.1)
Bilateral 1 (0.5) 1 (0.5)
Signiﬁcant PVR 12 (8.8) 11 (8.0) 0.831
Periurethral irregularity or vascularity 6 (2.8) 0 0.030
Data are presented as n (%).
ED¼ ejaculatory duct; PVR¼ postvoid residual; PZ¼ peripheral zone; SV ¼ seminal
vesicle; TZ ¼ transitional zone; VD ¼ vas deferens.
Figure 2. Transitional zone (TZ) ﬁndings. (A) Normal TZ. (B) Enlarged median lobe. (C)
Cystic spaces (right side).
Figure 3. Seminal vesicles (SV) and vas deferens (VD) ﬁndings. (A) Cystic spaces. (B)
Calciﬁcations. (C) Bilateral dilation of SV and VD.
D.E. Zilberman et al. / Urological Science 27 (2016) 40e44 43patients with nonbacterial prostatitis and 22 patients without any
complaints. Similar to our ﬁndings, the study group demonstrated
more calciﬁcations comparedwith the control group, whereas in all
other parameters their ﬁndings differed: prostate volume was
identical in both groups, and the study group demonstrated less
hypervascularity, fewer elongated SVs, andmore hypoechogenicity.
Yet, their study sample was too small to declare their ﬁndings as
statistically signiﬁcant.To the best of our knowledge, this is the largest study to date on
this topic with an age-matched control group for comparison and
with a single operator for the performance of the DRE and the TRUS
imaging and its interpretation. Despite these advantages the main
limitations of the current study were its retrospective nature and
the consequent lack of single objective estimation for patients'
clinical complaints (i.e., medical history and laboratory tests ob-
tained by a single physician and a single laboratory).
Figure 4. Ejaculatory duct dilation.
D.E. Zilberman et al. / Urological Science 27 (2016) 40e4444Nevertheless, our ﬁndings suggest that although there were
apparent differences in sonographic ﬁndings demonstrated be-
tween CP/CPPS patients and age-matched controls, the differences
were nonspeciﬁc. In other words, we were unable to attribute the
entirety or at least most of the differences to the study group, the
sonographic ﬁndings apparently were not unique to the study
group, and we were unable to identify sonographic ﬁndings that
will make a clear-cut diagnosis of CP/CPPS. Moreover, none of the
patients in the study group has been given a different diagnosis or
treatment following TRUS.Conﬂicts of interest
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